Roche, Innovent ink licensing deal for lung cancer drug

rafal_olechowski Chinese biotech Innovent Biologics ( OTCPK:IVBIY ) ( OTCPK:IVBXF ) has entered into a collaboration and licensing agreement with Roche ( OTCQX:RHHBY ) to develop its experimental lung cancer therapy IBI3009. The antibody-drug conjugate has already indicated potential anti-tumor activity with a favorable safety profile in.